Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 3 | Molecular Cancer

Figure 3

From: Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin

Figure 3

Cisplatin sensitizes MPM cells to Mapatumumab- or Lexatumumab- mediated cytotoxicity. Human agonistic TRAIL receptor antibodies Mapatumumab (Mapa) and Lexatumumab (Lexa) enhance the activity of cisplatin in MPM cells lines. H226 and ZL55 cells were cultured with or without 2 μM cisplatin for 24 h. Cells were subsequently left untreated or treated with 10 μg/ml Mapatumumab or Lexatumumab and cell proliferation was determined 72 h later as described under experimental procedures. Absorbance values obtained with untreated cells maintained under identical conditions were taken as 100%. Data represent means of three independent experiments and bars indicate standard deviations. **, P < 0.01 and *, P < 0.05 compared to cells not treated with anti-TRAIL receptor antibodies.

Back to article page